keyword
MENU ▼
Read by QxMD icon Read
search

castration refractory

keyword
https://www.readbyqxmd.com/read/28183253/optimal-management-of-prostate-cancer-based-on-its-natural-clinical-history
#1
Gaetano Facchini, Francesco Perri, Gabriella Misso, Carmine D Aniello, Giuseppina Della Vittoria Scarpati, Sabrina Rossetti, Chiara Della Pepa, Salvatore Pisconti, Gerhard Unteregger, Alessia Cossu, Michele Caraglia, Massimiliano Berretta, Carla Cavaliere
Prostate cancer is the most common malignancy in males and, despite a marked improvement in diagnostic techniques, a not small percentage of prostate tumours is still diagnosed in advanced stage. It is now clear that prostate cancer passes through distinct phases during its natural history, starting from an initial phase, in which the disease has a locoregional extent, until a very late phase when it becomes refractory to hormone therapy. It is important to distinguish between local disease, in which tumor may be considered localized in the gland and a systemic disease characterized by high tumor burden and/or dissemination of circulating tumour cells...
February 8, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28156633/evaluation-of-the-palliative-benefit-and-toxicity-of-ra-223-treatment-of-men-with-hormone-refractory-prostate-cancer-in-a-community-setting
#2
Bide Xiong, Fang Liu, Elizabeth Garber, James Wheeler
: 225 Background: The ALSYMCA (Alpharadin in Symptomatic Prostate Cancer) trial was a phase III, placebo controlled, randomized trial in which 921 men with bone metastasis from hormone refractory prostate cancer (HRPC) were randomly assigned to receive radium-223 (Ra-223) or placebo. Ra-223 produced a 30% survival benefit, with a median survival of 14.9 months compared to 11.3 months for patients treated with a placebo, which led to FDA approval in 2013. METHODS: We identified through the nuclear medicine records 11 patients who started Ra-223 between March 15, 2013 and December 10, 2015...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28126272/prostate-specific-antigen-response-in-black-and-white-patients-treated-with-abiraterone-acetate-for-metastatic-castrate-resistant-prostate-cancer
#3
Sundhar Ramalingam, Michael S Humeniuk, Rachel Hu, Julia Rasmussen, Patrick Healy, Yuan Wu, Michael R Harrison, Andrew J Armstrong, Daniel J George, Tian Zhang
PURPOSE: Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled few black patients, a population with a higher mortality from prostate cancer. Our primary objective was to determine differences in response to AA between B and W patients. METHODS: We performed a retrospective case-control study of B vs...
January 23, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28111042/-immunotherapy-in-uropathology
#4
Virginie Verkarre, Hélène Roussel, Clémence Granier, Eric Tartour, Yves Allory
The algorithms for treatment of metastatic cancers are evolving due to positive results obtained with immunotherapy. Therapeutics approaches to stimulate the immune system have already been used in the treatment of kidney and bladder cancer, such as the administration of cytokines and BCG therapy, confirming the immunogenicity of these tumors. The aim of immunotherapies is not only to activate the immune system against tumor cells, but also to take into account the tumor-induced suppressive microenvironment, in particular by removing the anergy of T-cell lymphocytes, and by targeting the co-stimulation inhibitors molecules...
January 19, 2017: Annales de Pathologie
https://www.readbyqxmd.com/read/28089304/management-of-prostate-cancer-in-elderly-patients-recommendations-of-a-task-force-of-the-international-society-of-geriatric-oncology
#5
REVIEW
Jean-Pierre Droz, Gilles Albrand, Silke Gillessen, Simon Hughes, Nicolas Mottet, Stéphane Oudard, Heather Payne, Martine Puts, Gilbert Zulian, Lodovico Balducci, Matti Aapro
CONTEXT: Prostate cancer is the most frequent male cancer. Since the median age of diagnosis is 66 yr, many patients require both geriatric and urologic evaluation if treatment is to be tailored to individual circumstances including comorbidities and frailty. OBJECTIVE: To update the 2014 International Society of Geriatric Oncology (SIOG) guidelines on prostate cancer in men aged >70 yr. The update includes new material on health status evaluation and the treatment of localised, advanced, and castrate-resistant disease...
January 11, 2017: European Urology
https://www.readbyqxmd.com/read/28069826/endostatin-inhibits-androgen-independent-prostate-cancer-growth-by-suppressing-nuclear-receptor-mediated-oxidative-stress
#6
Joo Hyoung Lee, Minsung Kang, Hong Wang, Gurudatta Naik, James A Mobley, Guru Sonpavde, W Timothy Garvey, Victor M Darley-Usmar, Selvarangan Ponnazhagan
Androgen-deprivation therapy has been identified to induce oxidative stress in prostate cancer (PCa), leading to reactivation of androgen receptor (AR) signaling in a hormone-refractory manner. Thus, antioxidant therapies have gained attention as adjuvants for castration-resistant PCa. Here, we report for the first time that human endostatin (ES) prevents androgen-independent growth phenotype in PCa cells through its molecular targeting of AR and glucocorticoid receptor (GR) and downstream pro-oxidant signaling...
January 9, 2017: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/28052297/androgen-receptor-gene-copy-number-and-protein-expression-in-treatment-na%C3%A3-ve-prostate-cancer
#7
Filip Poelaert, Candy Kumps, Nicolaas Lumen, Stephanie Verschuere, Louis Libbrecht, Marleen Praet, Sylvie Rottey, Tom Claeys, Piet Ost, Karel Decaestecker, Gert De Meerleer, Charles Van Praet
OBJECTIVES: To evaluate the androgen receptor (AR) gene copy number in androgen deprivation therapy (ADT) treatment-naïve prostate cancer (PCa) patients and to evaluate the corresponding AR protein expression and assess the association between these features and prognostic factors. MATERIALS AND METHODS: Chromosome X and AR gene copy number, using fluorescence-in-situ-hybridization, and epithelial-stromal AR expression, using AR immunohistochemistry, were analyzed in 62 ADT treatment-naïve PCa patients and 8 castration-refractory patients...
January 5, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/27960186/cabazitaxel-in-metastatic-castration-resistant-prostate-cancer-patients-progressing-after-docetaxel-a-prospective-single-center-study
#8
Giuseppe Cicero, Rossella De Luca, Patrizia Dorangricchia, Antonio Galvano, Giuseppe Lo Re, Vincenzo Serretta, Nino Dispensa, Francesco Dieli
PURPOSE: The present study aims to evaluate the efficacy of cabazitaxel in combination with prednisone treatment in Italian patients affected by hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel plus prednisone. METHODS: Thirty patients with mCRPC were enrolled between June 2013 and January 2016 (the last follow-up was in January 2016). Cabazitaxel was used according to the summary of product characteristics and administered at a dose of 25 mg/m2 every 3 weeks plus oral prednisone at a dose of 5-mg tablets twice a day continuously...
2017: Oncology
https://www.readbyqxmd.com/read/27922871/excellent-response-to-177lu-psma-617-radioligand-therapy-in-a-patient-with-advanced-metastatic-castration-resistant-prostate-cancer-evaluated-by-68ga-psma-pet-ct
#9
Wolfgang Roll, Axel Bode, Matthias Weckesser, Martin Bögemann, Kambiz Rahbar
Recently radiolabeled ligands targeting prostate specific membrane antigen (PSMA) have been introduced for diagnostics and treatment of prostate cancer. Labeled with Lutetium, PSMA radioligand therapy (RLT) is one of the most promising new treatments of metastatic castration refractory prostate cancer. We present images of Ga-PSMA PET/CT and parameters of response of a 75-year-old heavily pretreated metastatic castration refractory prostate cancer patient with extended bone metastases, showing an extraordinary biochemical response in PSA-levels concordant to SUV decline in bone metastases...
February 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27872023/multiple-orgasms-in-men-what-we-know-so-far
#10
REVIEW
Erik Wibowo, Richard J Wassersug
INTRODUCTION: There is much popular discussion on strategies to facilitate multiple orgasms in men (ie, 100,000+ hits in Google), yet the topic has not received an objective comprehensive review in the literature. AIM: To review the literature on male multiple orgasms. METHODS: We searched the literature for publications on "male multiple orgasms" and factors influencing male multiple orgasms in Google, PubMed, and PsychINFO. This yielded 15 relevant publications...
April 2016: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/27765852/targeting-binding-function-3-of-the-androgen-receptor-blocks-its-co-chaperone-interactions-nuclear-translocation-and-activation
#11
Nada Lallous, Eric Leblanc, Ravi S N Munuganti, Mohamed D H Hassona, Nader Al Nakouzi, Shannon Awrey, Helene Morin, Mani Roshan-Moniri, Kriti Singh, Sam Lawn, Takeshi Yamazaki, Hans H Adomat, Christophe Andre, Mads Daugaard, Robert N Young, Emma S Tomlinson Guns, Paul S Rennie, Artem Cherkasov
The development of new antiandrogens, such as enzalutamide, or androgen synthesis inhibitors like abiraterone has improved patient outcomes in the treatment of advanced prostate cancer. However, due to the development of drug resistance and tumor cell survival, a majority of these patients progress to the refractory state of castration-resistant prostate cancer (CRPC). Thus, newer therapeutic agents and a better understanding of their mode of action are needed for treating these CRPC patients. We demonstrated previously that targeting the Binding Function 3 (BF3) pocket of the androgen receptor (AR) has great potential for treating patients with CRPC...
December 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27665358/kifc1-induces-resistance-to-docetaxel-and-is-associated-with-survival-of-patients-with-prostate-cancer
#12
Yohei Sekino, Naohide Oue, Yoshinori Shigematsu, Akira Ishikawa, Naoya Sakamoto, Kazuhiro Sentani, Jun Teishima, Akio Matsubara, Wataru Yasui
OBJECTIVES: Prostate cancer (PCa) is a common malignancy worldwide. Docetaxel has been an important treatment option for patients with metastatic castration-resistant prostate cancer (CRPC). However, nearly all patients with CRPC treated with docetaxel eventually become refractory. In the present study, we analyzed the expression and distribution of kinesin family member C1 (KIFC1) in human PCa by immunohistochemistry and examined the effect of inhibiting KIFC1 expression on docetaxel resistance...
January 2017: Urologic Oncology
https://www.readbyqxmd.com/read/27607162/successful-treatment-of-hepatic-metastases-of-hormone-refractory-prostate-cancer-using-radioligand-therapy-with-177lu-psma-617
#13
Xiao Wei, Carl Schlenkhoff, Claudia Sopora, Markus Essler, Hojjat Ahmadzadehfar
An 81-year-old castrate-resistant prostate cancer man with multiple lymph node, bone, and hepatic metastases received four cycles of Lu-PSMA-617 treatments at our department from May to December 2015. All of his liver metastases showed PSMA expression in Ga-PSMA PET performed before the first cycle. Under this therapy, all of the metastases showed significant regression in size and PSMA expression over time.
November 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27587707/predictors-of-response-to-radioligand-therapy-of-metastatic-castrate-resistant-prostate-cancer-with-177lu-psma-617
#14
Justin Ferdinandus, Elisabeth Eppard, Florian Gärtner, Stefan Kürpig, Rolf Fimmers, Anna Yordanova, Stefan Hauser, Georg Feldmann, Markus Essler, Hojjat Ahmadzadehfar
PURPOSE: Radioligand therapy (RLT) with (177)Lu-PSMA-617 (Lu-PSMA-617) (prostate-specific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we evaluated the effect of different pre-therapeutic parameters on the therapeutic response measured by prostate-specific antigen(PSA) two months after RLT. METHODS: RLT was performed in 40 hormone and/or chemo refractory patients with distant metastases and progressive disease (mean age: 71...
September 1, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27486306/galeterone-for-the-treatment-of-advanced-prostate-cancer-the-evidence-to-date
#15
REVIEW
Diogo A Bastos, Emmanuel S Antonarakis
Major advances have been achieved recently in the treatment of metastatic castration-resistant prostate cancer, resulting in significant improvements in quality of life and survival with the use of several new agents, including the next-generation androgen receptor (AR)-targeted drugs abiraterone and enzalutamide. However, virtually all patients will eventually progress on these therapies and most will ultimately die of treatment-refractory metastatic disease. Recently, several mechanisms of resistance to AR-directed therapies have been uncovered, including the AR splice variant 7 (AR-V7), which is a ligand-independent constitutionally-active form of the AR that has been associated with poor outcomes to abiraterone and enzalutamide...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27473672/growth-inhibition-by-testosterone-in-an-androgen-receptor-splice-variant-driven-prostate-cancer-model
#16
Daisuke Nakata, Kazuhide Nakayama, Tsuneo Masaki, Akira Tanaka, Masami Kusaka, Tatsuya Watanabe
BACKGROUND: Castration resistance creates a significant problem in the treatment of prostate cancer. Constitutively active splice variants of androgen receptor (AR) have emerged as drivers for resistance to androgen deprivation therapy, including the next-generation androgen-AR axis inhibitors abiraterone and enzalutamide. In this study, we describe the characteristics of a novel castration-resistant prostate cancer (CRPC) model, designated JDCaP-hr (hormone refractory). METHODS: JDCaP-hr was established from an androgen-dependent JDCaP xenograft model after surgical castration...
December 2016: Prostate
https://www.readbyqxmd.com/read/27435207/cpa-7-influences-immune-profile-and-elicits-anti-prostate-cancer-effects-by-inhibiting-activated-stat3
#17
Meihua Liang, Fei Zhan, Juan Zhao, Qi Li, Jiazi Wuyang, Guannan Mu, Dianjun Li, Yanqiao Zhang, Xiaoyi Huang
BACKGROUND: Platinum-based chemotherapy is emerging as the first line of treatment for castration resistant prostate cancer. Among the family of platinum (IV)-based compounds, a member known as CPA-7 inhibits the growth of multiple cancer cell lines. However, how and to what extent CPA-7 elicits its anti-prostate cancer effects in vivo is largely unknown. METHODS: In this study, we firstly assessed the potential toxicity of the synthesized CPA-7 in a prostate cancer model as well as in normal mice...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27434595/trapeze-a-randomised-controlled-trial-of-the-clinical-effectiveness-and-cost-effectiveness-of-chemotherapy-with-zoledronic-acid-strontium-89-or-both-in-men-with-bony-metastatic-castration-refractory-prostate-cancer
#18
Nicholas James, Sarah Pirrie, Ann Pope, Darren Barton, Lazaros Andronis, Ilias Goranitis, Stuart Collins, Duncan McLaren, Joe O'Sullivan, Chris Parker, Emilio Porfiri, John Staffurth, Andrew Stanley, James Wylie, Sharon Beesley, Alison Birtle, Janet Brown, Prabir Chakraborti, Martin Russell, Lucinda Billingham
BACKGROUND: Bony metastatic castration-refractory prostate cancer is associated with a poor prognosis and high morbidity. TRAPEZE was a two-by-two factorial randomised controlled trial of zoledronic acid (ZA) and strontium-89 (Sr-89), each combined with docetaxel. All have palliative benefits, are used to control bone symptoms and are used with docetaxel to prolong survival. ZA, approved on the basis of reducing skeletal-related events (SREs), is commonly combined with docetaxel in practice, although evidence of efficacy and cost-effectiveness is lacking...
July 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27370570/bioactive-natural-products-for-chemoprevention-and-treatment-of-castration-resistant-prostate-cancer
#19
REVIEW
Georgios Kallifatidis, James J Hoy, Bal L Lokeshwar
Prostate cancer (PCa), a hormonally-driven cancer, ranks first in incidence and second in cancer related mortality in men in most Western industrialized countries. Androgen and androgen receptor (AR) are the dominant modulators of PCa growth. Over the last two decades multiple advancements in screening, treatment, surveillance and palliative care of PCa have significantly increased quality of life and survival following diagnosis. However, over 20% of patients initially diagnosed with PCa still develop an aggressive and treatment-refractory disease...
October 2016: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/27356095/epi-001-a-compound-active-against-castration-resistant-prostate-cancer-targets-transactivation-unit-5-of-the-androgen-receptor
#20
Eva De Mol, R Bryn Fenwick, Christopher T W Phang, Victor Buzón, Elzbieta Szulc, Alex de la Fuente, Albert Escobedo, Jesús García, Carlos W Bertoncini, Eva Estébanez-Perpiñá, Iain J McEwan, Antoni Riera, Xavier Salvatella
Castration-resistant prostate cancer is the lethal condition suffered by prostate cancer patients that become refractory to androgen deprivation therapy. EPI-001 is a recently identified compound active against this condition that modulates the activity of the androgen receptor, a nuclear receptor that is essential for disease progression. The mechanism by which this compound exerts its inhibitory activity is however not yet fully understood. Here we show, by using high resolution solution nuclear magnetic resonance spectroscopy, that EPI-001 selectively interacts with a partially folded region of the transactivation domain of the androgen receptor, known as transactivation unit 5, that is key for the ability of prostate cells to proliferate in the absence of androgens, a distinctive feature of castration-resistant prostate cancer...
September 16, 2016: ACS Chemical Biology
keyword
keyword
98286
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"